Dihydroergocristine mesylate |
Katalog-Nr.GC13256 |
Dihydroergocristinmesylat (DHEC-Mesylat) ist ein Inhibitor der γ-Sekretase (GSI), reduziert die Produktion der Amyloid-β-Peptide der Alzheimer-Krankheit, bindet direkt an γ-Sekretase und Nicastrin mit Gleichgewichtsdissoziationskonstanten (Kd) von 25,7 nM und 9,8 μM bzw..
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 24730-10-7
Sample solution is provided at 25 µL, 10mM.
Dihydroergocristine mesylate (DHEC mesylate) is a inhibitor of γ-secretase (GSI), reduces the production of the Alzheimer's disease amyloid-β peptides, binds directly to γ-secretase and Nicastrin with equilibrium dissociation constants (Kd) of 25.7 nM and 9.8 μM, respectively[1].
Dihydroergocristine (DHEC) (2-20 μM; 24 hours) has an IC50 value of 25 μM for inhibiting the activity of γ-secretase in T100 cells without affecting cell viability[1]. Dihydroergocristine (2-20 μM; 24 hours) inhibits cellular Aβ production and causes a dose-dependent accumulation of carboxy-terminal fragments of APP (APP-CTFs) in HEK293 and decreases γ-secretase activity in fibroblast cells[1].
References:
[1]. Lei X, et al. The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer's disease amyloid-β peptides. Sci Rep. 2015 Nov 16;5:16541.
Average Rating: 5
(Based on Reviews and 32 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *